University of Florida Health

Running trials

• Not yet recruiting

  The Study of Brave-LC LDN Treatment Trial

  NCT07916259· Phase 3· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Recruiting

  PULmonary Stimulation for Asthma Relief

  NCT07709754· Spiro Medical, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Magnetoencephalography (MEG) Pilot Study

  NCT07446192· University of Florida· Source

• Recruiting

  Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

  NCT07025148· Phase 4· University of Florida· Source

• Recruiting

  Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

  NCT06514898· Phase 1· University of Florida· Source

• Active, not recruiting

  RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

  NCT05660408· Phase 1/2· University of Florida· Source

• Active, not recruiting

  Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant

  NCT06699797· Envoy Medical Corporation· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Active, not recruiting

  RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

  NCT06389591· Phase 1· University of Florida· Source

• Recruiting

  Registry for Stage 2 Type 1 Diabetes

  NCT06481904· Sanofi· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source

• Active, not recruiting

  A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  NCT06372145· Phase 3· Sanofi· Source

• Recruiting

  RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  NCT06121297· Phase 1/2· Cabaletta Bio· Source

• Recruiting

  An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

  NCT06447025· Phase 2· Larimar Therapeutics, Inc.· Source

• Recruiting

  The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

  NCT05564936· Ad scientiam· Source

• Enrolling by invitation

  A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

  NCT05979441· Phase 3· argenx· Source

• Active, not recruiting

  IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

  NCT05353530· Phase 1· University of Florida· Source

• Recruiting

  SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  NCT05303519· Phase 3· Nuvation Bio Inc.· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Active, not recruiting

  Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

  NCT05573984· PYC Therapeutics· Source

• Recruiting

  A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

  NCT04573140· Phase 1· University of Florida· Source

• Active, not recruiting

  Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

  NCT04700124· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

  NCT04763200· Abiomed Inc.· Source

• Active, not recruiting

  Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

  NCT04644575· Phase 3· Bioverativ, a Sanofi company· Source

• Recruiting

  A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

  NCT04333706· Phase 1/2· University of Southern California· Source

• Active, not recruiting

  SELUTION SLR™ 014 In-stent Restenosis

  NCT04280029· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

  NCT03899649· Angiodynamics, Inc.· Source

• Enrolling by invitation

  IVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry

  NCT04520347· University of California, Los Angeles· Source

• Active, not recruiting

  Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

  NCT03405792· Phase 2· University of Florida· Source

• Active, not recruiting

  Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

  NCT02603341· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  NCT02693535· Phase 2· American Society of Clinical Oncology· Source

• Active, not recruiting

  Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

  NCT06855394· University of Florida· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Glioblastoma2 recruiting
• Asthma1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Essential tremor1 recruiting
• High blood pressure1 recruiting
• Long COVID and ME/CFS1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

  NCT06455826· Phase 1· PYC Therapeutics· Source

• Completed

  A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

  NCT05864846· Phase 4· Jazz Pharmaceuticals· Source

• Completed

  Evaluation in STEMI Patients Using FDY-5301

  NCT04837001· Phase 3· Faraday Pharmaceuticals, Inc.· Source

• Completed

  Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

  NCT04972097· Angiodynamics, Inc.· Source

• Completed

  Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

  NCT05220501· Sunnybrook Health Sciences Centre· Source

• Completed

  Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

  NCT05028634· Phase 3· Celgene· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

  NCT04410991· Phase 3· Sanofi· Source

• Terminated

  LITT and Pembrolizumab in Recurrent Brain Metastasis

  NCT04187872· Phase 1· University of Florida· Source

• Completed

  A Gene Transfer Study for Hemophilia A

  NCT03003533· Phase 1/2· Spark Therapeutics, Inc.· Source

• Completed

  Network Analysis of Urinary Molecular Signature Complements Clinical Data to Predict Postoperative Acute Kidney Injury

  NCT02114138· University of Florida· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Parkinson disease83 works · 0 trials
• Type 1 diabetes45 works · 1 trial
• Sarcoma23 works · 0 trials
• Aortic aneurysm18 works · 0 trials
• Dystonia18 works · 0 trials
• Congenital heart disease16 works · 0 trials
• Hodgkin lymphoma12 works · 0 trials
• Pulmonary arterial hypertension10 works · 1 trial
• Essential tremor9 works · 1 trial
• Duchenne muscular dystrophy9 works · 0 trials
• Tourette syndrome9 works · 0 trials
• Lewy body dementia8 works · 0 trials
• Hydrocephalus8 works · 0 trials
• Brain aneurysm7 works · 0 trials
• Liver cirrhosis5 works · 0 trials
• High blood pressure4 works · 1 trial
• Retinitis pigmentosa4 works · 2 trials
• Multiple system atrophy4 works · 0 trials
• Gastroparesis3 works · 0 trials